Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT)…
By I. Smith, Mitchell Dowsett, S. Ebbs, J. Dixon, A. Skene, J. Blohmer, S. Ashley, S. Francis, Irene Boeddinghaus, G. Walsh. Journal of Clinical Oncology, 2005
757 citations recorded by the source corpus.
Subfields: Cancer Research, Genetics, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/e0b0e2313f794ea5ec60c8b15132114d02248c22
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
Citations in the corpus
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015, background): “If such drugs cannot be replaced, a switch to alternative treatment, i.e. AIs, should be considered [IV, B] [116, 117].”
- Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline (2021, methodology): “The IMPACT (Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen) double-blind clinical trial randomly assigned 330 postmenopausal women with estrogen receptor–positive (ER-positive), nonmetastatic, invasive, operable breast cancer to neoadjuvant anastrozole (n5 113), tamoxifen ”
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) (2014, background): “A number of studies have demonstrated significant activity of endocrine therapy, particularly in luminal A-like disease [37–40].”